CoDa Therapeutics Inks $19.2M Series B
San Diego-based CoDa Therapeutics Inc. has raised $19.2 million in a first closing of Series B financing. Existing shareholders Domain Associates, GBS Venture Partners and BioPacificVentures participated in the round. CoDa is a clinical-stage biopharmaceutical company working to develop drug therapies for wounds that do not heal properly, including venous leg and diabetic foot ulcers. The company will use the Series B financing for continued development.
18 April 2011•4 mins read
